Sucampo Pharmaceuticals Hopes for Drug Approval in United Kingdom

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), a biotechnology firm in Bethesda is taking on multiple matters to keep its revenue stream growing.

Chairman and Chief Executive Officer, Ryuji Ueno, M.D., Ph.D., Ph.D., said in a statement during its second quarter 2011, financial results that the company has filed a marketing application in the U.K. for approval of its drug lubiprostone to treat chronic idiopathic constipation.

At the same time the company said it has had to increase expenses significantly to protect its products in a law-suit involving Takeda Pharmaceutical Companyin the United States.

Stocks, Trading and Investing